Clinical Track

Oral Presentations

MO09 - Assessing Provider Adherence to Transgender Clinical Practice Guidelines: Are We Providing Perfect Care?

Presenter(s)

• ES

  Erika Sullivan, MD, MS, MS

  Assistant Professor of Clinical Medicine, Medical Operations Officer for DFPM, PCMH Liason for DFPM, Co-Medical Director of the University Transgender Health Program
  University of Utah Department of Family and Preventive Medicine
  University of Utah, Department of Family and Preventive Medicine

  Nothing to disclose

Co-Presenter(s)

• BK

  Bernadette Kiraly, MD

  Co-Medical Director, Transgender Health Program
  University of Utah
  University of Utah

  Nothing to disclose
• RB

  Robin Brown

There are multiple societies and organizations that have issued either standards of care or clinical guidelines for transgender hormone treatment. We sought to evaluate our group's adherence to these recommendations. We hypothesized that we provide competent hormone therapy to our transgender patients, but that there is likely also room for standardization and quality improvement tools to drive us towards "Perfect Care."

Methods : 1. Created a table that cross walks all available guidelines and standards of care to define a consensus statement regarding monitoring hormone therapy safety and adherence
2. We defined the essential elements of safety and adherence to these guidelines which described "Perfect Care"
3. We performed a chart review to assess our baseline performance and adherence to the definition of perfect care
4. We proposed interventions, in the form of mini-process improvement cycles, to improve the care we provide to the TG/GNC community that we serve

Results : No results at the time of the writing of this proposal. We are in the process of collecting the data for analytics. We will present our definitions for Perfect Care and the baseline performance of our group vis-à-vis these guidelines if selected for a workshop at the conference.

Conclusions : Our research attempts to define quality metrics that can provide the basis for data-driven quality improvement work in transgender medicine. We hope to show that our group is practicing high quality and data-driven care, but that with all programs, there is room for improvement. We recognize that transgender medicine is well poised for development of quality improvement studies, inquiry, research and scholarship.

Learning Objectives:

• Understand what similarities and differences exist in the published and informatl literaute in terms of strategies and guidelines for prescribing, dosing, titrating and monitoring transmasculine hormone therapy.
• Describe the consensus guidlines chosen by this group that constitutes our definition of “Perfect Care.”
• Describe the baseline data obtained by this group, obtained through chart review, which shows adherence to, and deviations from, “Perfect Care.”
• Demonstrate awareness of limitations of our study design and results and areas of future research

1. Understand what similarities and differences exist in the published and informatl literaute in terms of strategies and guidelines for prescribing, dosing, titrating and monitoring transmasculine hormone therapy.
2. Describe the consensus guidlines chosen by this group that constitutes our definition of “Perfect Care.”
3. Describe the baseline data obtained by this group, obtained through chart review, which shows adherence to, and deviations from, “Perfect Care.”
4. Demonstrate awareness of limitations of our study design and results and areas of future research